Seres Therapeutics, Inc.

NASDAQ:MCRB

Biotechnology

Healthcare
$5.28 +1.70%

+$0.11 today

Market cap
$51.13M
Beta
0.11
P/E (TTM)
-1.3
EPS (TTM)
-$4.89
52W Low $5.31High $29.98

Volume 0.04M

Average 0.06M

MCRB Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Seres Therapeutics, Inc.NASDAQ: MCRB

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin at -118.2%

Gross margin was -118.2% in Q1 FY2026. On a trailing-twelve-month basis it was -20.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-118.2%-3370.0 pp QoQ
Last fiscal yearDec 2025
-423.8%— YoY
LTMMar 2026
-20.9%— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3 years———
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-423.8%
Year-over-year change
—

Gross Margin vs competitors

How MCRB compares with its peers on the latest reported figures

  • MCRB's LTM Mar 2026 gross margin of -20.9% is the lowest of the 5 companies compared; the peer median is 74.8%.
MCRB Competitors Peer median
Gross Margin for MCRB and competitors
Company Period LTM level YoY 3-year change
INOInovio Pharmaceuticals, Inc.FY2025100.0% +0.0 pp+0.0 pp
SPROSpero Therapeutics, Inc.LTM Mar 2026100.0% +296.0 pp+0.0 pp
IRDOpus Genetics, Inc.LTM Mar 202649.6% +6.6 pp+0.0 pp
SEERSeer, Inc.LTM Mar 202648.3% +18.6 pp+9.2 pp
MCRBSeres Therapeutics, Inc.LTM Mar 2026-20.9% ——
ABOSAcumen Pharmaceuticals, Inc.FY2025— ——
HURATuHURA Biosciences, Inc.FY2025— ——
CGTXCognition Therapeutics, Inc.FY2025— ——
ACTUActuate Therapeutics IncFY2025— ——
Peer median (excluding MCRB) 74.8%+12.6 pp+0.0 pp

Competitors are the stored peer set for MCRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue144.93M000789K
Cost of Revenue0019.34M3.53M4.13M
Gross Profit144.93M0(19.34M)(3.53M)(3.34M)
Gross Margin100.0%———-423.8%
Research & Development141.89M109.65M117.6M64.6M49.06M
Selling, General & Admin69.26M70.26M77.5M53.18M39.16M
Operating Expenses209.42M179.91M175.76M117.78M90.63M
Depreciation & Amortization5.95M6.63M6.24M5.47M4.13M
EBITDA(56.72M)(170.93M)(181.42M)(120.3M)9.83M
EBITDA Margin-39.1%———1245.8%
Operating Income(64.49M)(179.91M)(195.1M)(121.32M)(93.97M)
Operating Margin-44.5%———-11910.1%
Interest Income2.87M3.06M7.3M3.97M2.23M
Interest Expense2.91M6.02M13.18M00
Other Income / Expenses(1.09M)(3.67M)4.97M(4.46M)99.67M
Income Before Tax(65.58M)(183.58M)(190.13M)(125.77M)5.7M
Pre-Tax Margin-45.2%———721.9%
Income Tax Expense00000
Net Income(65.58M)(250.16M)(113.72M)(146.57M)5.7M
Net Margin-45.2%———721.9%
EPS (Basic)(14.30)(46.29)(17.77)(18.86)0.64
EPS (Diluted)(14.30)(46.29)(17.77)(18.86)0.64
Weighted Avg Shares4.59M5.4M6.4M7.77M8.86M
Weighted Avg Shares (Diluted)4.59M5.4M6.4M7.77M8.87M

Seres Therapeutics, Inc.

NASDAQ:MCRB

Intrinsic Alpha fair value

Locked

Current Price

$5.28

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.